mr. marlo, you've got a separate area. if this all came to pass and it came back here to the finance committee, and we had to start doing some serious looking at where you take things out of the health care system, particularly medicare and medicaid, you want to make some suggestions? >> well, i think that similar to the discussion we had, i think that's also true with our health care system, specifically medicare and medicaid. i acknowledge one of the challenges we have and i think we have many opportunities to address the cost of medicare and medicaid and at the same time address some of the unnecessary costs and wasteful spending we're seeing. the example i gave earlier. $300 billion spent annually on unnecessary medical costs as a result of poor prescription drug compliance and adherence. so i would encourage us to look at both of those as potential solutions to that challenge, recognizing that there are things that we can do to take cost out of the system and at the same time, keep america

mr. marlo, i want to follow on my colleague, i think was referring to in terms of reprattation of foreign profits, i understand that c.v.s. caremark is not necessarily in that category, do you say in your testimony you are paying almost an effective 35% rate. and in essence by paying a high effective rate seems to me that your company and others similarly situated is basically paying for the burden of loopholes and avoidance behaviors of other companies. so do you believe that aggressive use of avoidance methods by competitors or the ability of companies to be able to take their overseas earnings and convert them in to -- into tax benefits here at home that ultimately provide them with a much lower effective rate, and you still paying a higher effective rate is a fair set of competitive standards? >> i think it certainly does create some competitive challenges for us. acknowledging that we compete with domestic companies as well as foreign nationals. that have the opportunity to have a lower ta